UBS Group
AKRO

UBS Group’s Akero Therapeutics AKRO Stock Holding History

UBS Group’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-66,900
Closed -$2.56M – 8846
2023
Q1 		$2.56M Hold
66,900
– – ﹤0.01% 3166
2022
Q4 		$3.67M Buy
+66,900
New +$2.87M ﹤0.01% 2793

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group's AKRO Position: Q4 2025 in Review

UBS Group sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 335,678 shares — an estimated $15.9M sold.

UBS Group first reported a position in AKRO in Q2 2019 and held it in 26 quarters. The position peaked at $108M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • UBS Group reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • UBS Group sold 335,678 Akero Therapeutics shares in Q4 2025, an estimated $15.9M.
  • UBS Group first reported a position in Akero Therapeutics in Q2 2019 and held it in 26 quarters.
  • UBS Group's Akero Therapeutics position peaked at $108M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.